KR102960903B1 - 흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물 - Google Patents

흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물

Info

Publication number
KR102960903B1
KR102960903B1 KR1020217010706A KR20217010706A KR102960903B1 KR 102960903 B1 KR102960903 B1 KR 102960903B1 KR 1020217010706 A KR1020217010706 A KR 1020217010706A KR 20217010706 A KR20217010706 A KR 20217010706A KR 102960903 B1 KR102960903 B1 KR 102960903B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
rpl554
particles
hfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217010706A
Other languages
English (en)
Korean (ko)
Other versions
KR20210073532A (ko
Inventor
피터 라이오넬 스파르고
필립 에이 헤이우드
Original Assignee
베로나 파마 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베로나 파마 피엘씨 filed Critical 베로나 파마 피엘씨
Publication of KR20210073532A publication Critical patent/KR20210073532A/ko
Application granted granted Critical
Publication of KR102960903B1 publication Critical patent/KR102960903B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217010706A 2018-10-09 2019-10-09 흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물 Active KR102960903B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (2)

Publication Number Publication Date
KR20210073532A KR20210073532A (ko) 2021-06-18
KR102960903B1 true KR102960903B1 (ko) 2026-05-04

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010706A Active KR102960903B1 (ko) 2018-10-09 2019-10-09 흡입에 의한 투여를 위한 hfa-134a 내의 rpl554를 포함하는 약제학적 조성물

Country Status (27)

Country Link
US (2) US20210379053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3960157A1 (cg-RX-API-DMAC7.html)
JP (2) JP7578587B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960903B1 (cg-RX-API-DMAC7.html)
CN (1) CN112912064B (cg-RX-API-DMAC7.html)
AU (1) AU2019358585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113167A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124943T1 (cg-RX-API-DMAC7.html)
DK (1) DK3820446T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899744T3 (cg-RX-API-DMAC7.html)
GB (1) GB2578093B (cg-RX-API-DMAC7.html)
HR (1) HRP20220053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057780T2 (cg-RX-API-DMAC7.html)
IL (1) IL282032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3820446T (cg-RX-API-DMAC7.html)
MX (2) MX2021003599A (cg-RX-API-DMAC7.html)
MY (1) MY207302A (cg-RX-API-DMAC7.html)
PH (1) PH12021550767A1 (cg-RX-API-DMAC7.html)
PL (1) PL3820446T3 (cg-RX-API-DMAC7.html)
PT (1) PT3820446T (cg-RX-API-DMAC7.html)
RS (1) RS62775B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102567UA (cg-RX-API-DMAC7.html)
SI (1) SI3820446T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074894A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102039B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505192A (ja) * 2015-02-11 2018-02-22 ヴェローナ ファーマ ピーエルシー ピリミド[6,1−a]イソキノリン−4−オン化合物の塩

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505192A (ja) * 2015-02-11 2018-02-22 ヴェローナ ファーマ ピーエルシー ピリミド[6,1−a]イソキノリン−4−オン化合物の塩

Also Published As

Publication number Publication date
EP3820446B1 (en) 2021-11-03
US20210379053A1 (en) 2021-12-09
AU2019358585B2 (en) 2025-01-16
GB2578093A (en) 2020-04-22
CN112912064A (zh) 2021-06-04
PL3820446T3 (pl) 2022-03-14
JP2024113096A (ja) 2024-08-21
SMT202200044T1 (it) 2022-05-12
BR112021006712A2 (pt) 2021-07-27
PT3820446T (pt) 2021-12-03
WO2020074894A1 (en) 2020-04-16
SI3820446T1 (sl) 2022-01-31
CY1124943T1 (el) 2023-01-05
CA3113167A1 (en) 2020-04-16
KR20210073532A (ko) 2021-06-18
IL282032B1 (en) 2026-01-01
IL282032A (en) 2021-05-31
DK3820446T3 (da) 2021-12-06
ZA202102039B (en) 2022-08-31
ES2899744T3 (es) 2022-03-14
JP7578587B2 (ja) 2024-11-06
GB201816447D0 (en) 2018-11-28
US20250049781A1 (en) 2025-02-13
EP3960157A1 (en) 2022-03-02
GB2578093B (en) 2020-11-18
MY207302A (en) 2025-02-15
RS62775B1 (sr) 2022-01-31
MX2024001499A (es) 2024-02-27
EP3820446A1 (en) 2021-05-19
IL282032B2 (en) 2026-05-01
PH12021550767A1 (en) 2021-10-04
SG11202102567UA (en) 2021-04-29
AU2019358585A1 (en) 2021-04-15
CN112912064B (zh) 2025-02-14
HUE057780T2 (hu) 2022-06-28
JP2022513566A (ja) 2022-02-09
JP7836853B2 (ja) 2026-03-27
LT3820446T (lt) 2021-12-10
HRP20220053T1 (hr) 2022-04-15
MX2021003599A (es) 2021-05-28

Similar Documents

Publication Publication Date Title
US20250049781A1 (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
EP2435024B1 (en) Compositions for respiratory delivery of active agents and associated methods and systems
JP2002521424A (ja) 医薬用エーロゾル製剤
NO334076B1 (no) Fremgangsmåte for fremstilling av tørrpulverinhaleringssammensetninger og multidose tørrpulverinhalator
CN103998039A (zh) 包含噻托溴铵的可吸入药物
EP1915129A2 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
JP2007508283A (ja) カルボン酸界面活性剤を含むエアロゾル製剤
JP6568511B2 (ja) 改善された医薬エアゾール製剤
HUP0302036A2 (hu) Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére
KR20120100901A (ko) 포모테롤 및 베클로메타손 디프로피오네이트의 약학적 에어로졸 제제
US20200163955A1 (en) Sterile compositions of indacaterol suitable for nebulization
WO2017089404A1 (en) Pharmaceutical composition
HK40061834A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
RU2813959C2 (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
HK40042852A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
HK40042852B (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
US20090180969A1 (en) Pharmaceutical formulation comprising an anticholinergic drug
WO2026094986A1 (en) Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof
US20170326067A1 (en) Pharmaceutical composition containing budesonide and formoterol
HK1169027B (en) Compositions for respiratory delivery of active agents and associated methods and systems
HK1169307B (en) Respiratory delivery of active agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)